Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Mar
01
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
SABCS 2025: Top Picks From a Breast Cancer Specialist
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo